Nordic MCL3 study: Y-90-ibritumomab-tiuxetan added to BEAM/C in non-CR patients before transplant in mantle cell lymphoma

Authors :: Arne Kolstad
Lone Bredo Pedersen
Unn-Merete Fagerli
Christer Sundström
Kirsten Grønbæk
Elisabeth Ralfkiaer
Erkki Elonen
Anne Kristine Lehmann
Kamelia Kostova-Aherdan
Eva Kimby
Jan Delabie
Trond Velde Bogsrud
Peter de Nully Brown
Annika Loft
Christian H. Geisler
Jukka Schildt
Mats Ehinger
Per Boye Hansen
Henrik Frederiksen
Anna Laurell
Marja-Liisa Karjalainen-Lindsberg
Riikka Räty
Hans Bentzen
Grete F. Lauritzsen
Mats Jerkeman
Herman Nilsson-Ehle
Source :: Blood; 123(19), pp 2953-2959 (2014), Kolstad, A, Laurell, A, Jerkeman, M, Grønbæk, K, Elonen, E, Räty, R, Pedersen, L B, Loft, A, Bogsrud, T V, Kimby, E, Hansen, P B, Fagerli, U-M, Nilsson-Ehle, H, Lauritzsen, G F, Lehmann, A K, Sundstrom, C, Karjalainen-Lindsberg, M-L, Ralfkiaer, E, Ehinger, M, Delabie, J, Bentzen, H, Schildt, J, Kostova-Aherdan, K, Frederiksen, H, Brown, P D N, Geisler, C H & Nordic Lymphoma Group 2014, ' Nordic MCL3 study : 90Y-ibritumomab-tiuxetan added to BEAM/C in non-CR patients before transplant in mantle cell lymphoma ', Blood, vol. 123, no. 19, pp. 2953-2959 . https://doi.org/10.1182/blood-2013-12-541953
Publication Year :: 2014
Publisher :: American Society of Hematology, 2014.
Abstract: The main objective of the MCL3 study was to improve outcome for patients not in complete remission (CR) before transplant by adding (90)Y-ibritumomab-tiuxetan (Zevalin) to the high-dose regimen. One hundred sixty untreated, stage II-IV mantle cell lymphoma patients

Subjects :: Melphalan
Male
Neoplasm, Residual
Time Factors
Clinical Trials and Observations
Kaplan-Meier Estimate
Lymphoma, Mantle-Cell
Biochemistry
Gastroenterology
Autologous stem-cell transplantation
hemic and lymphatic diseases
Antineoplastic Combined Chemotherapy Protocols
Etoposide
Cytarabine
Antibodies, Monoclonal
Hematology
Middle Aged
Prognosis
Combined Modality Therapy
3. Good health
surgical procedures, operative
Treatment Outcome
Rituximab
Female
medicine.drug
Adult
medicine.medical_specialty
Vincristine
Immunology
Transplantation, Autologous
Disease-Free Survival
Internal medicine
medicine
Humans
Cyclophosphamide
Aged
business.industry
Cell Biology
Radioimmunotherapy
medicine.disease
Minimal residual disease
Carmustine
Surgery
body regions
Multivariate Analysis
Mantle cell lymphoma
business
Stem Cell Transplantation

Language :: English
ISSN :: 15280020
Database :: OpenAIRE
Journal :: Blood; 123(19), pp 2953-2959 (2014), Kolstad, A, Laurell, A, Jerkeman, M, Grønbæk, K, Elonen, E, Räty, R, Pedersen, L B, Loft, A, Bogsrud, T V, Kimby, E, Hansen, P B, Fagerli, U-M, Nilsson-Ehle, H, Lauritzsen, G F, Lehmann, A K, Sundstrom, C, Karjalainen-Lindsberg, M-L, Ralfkiaer, E, Ehinger, M, Delabie, J, Bentzen, H, Schildt, J, Kostova-Aherdan, K, Frederiksen, H, Brown, P D N, Geisler, C H & Nordic Lymphoma Group 2014, ' Nordic MCL3 study : 90Y-ibritumomab-tiuxetan added to BEAM/C in non-CR patients before transplant in mantle cell lymphoma ', Blood, vol. 123, no. 19, pp. 2953-2959 . https://doi.org/10.1182/blood-2013-12-541953
Accession number :: edsair.doi.dedup.....a73676cf05e37923bddb650aeb8c8b53
Full Text :: https://doi.org/10.1182/blood-2013-12-541953

Full Text Access

Tools